Core Viewpoint - The company, Jinxin Fertility (01951), has made significant progress in the number of IVF cycles as of September 30, 2025, and maintains a strong confidence in the long-term development prospects of the industry and its future growth [1] Group 1: Company Performance - The overall decline in IVF cycles has slowed from -8.3% in the first half of 2024 to -5.2% in the first three quarters of 2025, indicating operational improvements [1] - The flagship hospital in Chengdu saw a reduction in IVF cycles' decline from -6.1% in the first half of 2025 to -1.9% in the nine months ending September 30, 2025 [1] - The Shenzhen hospital's improvement in IVF cycles is slower due to preparations for a relocation planned for the end of 2025 [1] Group 2: Industry Context - The company attributes its confidence to a solid industry foundation, ongoing favorable national policies, and continuous efforts to enhance clinical outcomes, optimize patient care, and diversify service offerings [1] - In the U.S. market, the delay in the implementation of California Senate Bill SB729, which requires commercial insurance to cover assisted reproduction, has led to a predictable decline in IVF cycles [1]
锦欣生殖(01951)前三季度在体外受精(IVF)取卵周期数提升方面取得显著进展